Attached files
| file | filename |
|---|---|
| EX-10.11 - FINDER AGREEMENT, DATED NOVEMBER 16, 2017, BETWEEN THE COMPANY AND EARLYBIRD - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | f10k2017ex10-11_bison.htm |
| EX-32.1 - CERTIFICATION - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | f10k2017ex32-1_bisoncap.htm |
| EX-31.2 - CERTIFICATION - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | f10k2017ex31-2_bisoncap.htm |
| EX-31.1 - CERTIFICATION - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | f10k2017ex31-1_bisoncap.htm |
| 10-K - ANNUAL REPORT - XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | f10k2017_bisoncapitalacq.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Bison Capital Acquisition Corp.(the “Company”) on Form 10-K for the year ended December 31, 2017 and for the period from October 7, 2016 (inception) through December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Fan Bu, Chief Financial Officer and Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Date: February 20, 2018
| /s/ Fan Bu | |
| Fan Bu | |
|
Chief Financial Officer and (Principal Accounting and Financial Officer) |